baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Index/Partizip. Zer.../ DE000SQ79WT1 /

1/23/2025 9:54:35 AM	Chg.+0.220	Bid10:39:45 AM	Ask10:39:45 AM	Underlying	Strike price	Expiration date	Option type
112.650EUR	+0.20%	112.710 Bid Size: 3,000	113.050 Ask Size: 3,000	TECDAX	- EUR	12/31/2078	Call

GlobeNewswire 7/22/2024 MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...

GlobeNewswire 6/12/2018 Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...

GlobeNewswire 12/20/2016 Medigene announces outlicensing of AAVLP technology

GlobeNewswire 12/13/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...

GlobeNewswire 12/6/2016 Medigene AG to be included in TecDAX Index

GlobeNewswire 12/6/2016 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...

GlobeNewswire 12/6/2016 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016

GlobeNewswire 11/28/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...

GlobeNewswire 11/17/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...

GlobeNewswire 11/15/2016 MorphoSys Raises EUR 115 million in Private Placement

GlobeNewswire 11/15/2016 Ad hoc: MorphoSys Raises EUR 115 million in Private Placement

GlobeNewswire 11/15/2016 MorphoSys to Raise Capital via a Private Placement of New Shares

GlobeNewswire 11/15/2016 Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares

GlobeNewswire 11/15/2016 MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...

GlobeNewswire 11/14/2016 MorphoSys to Present at Upcoming Investor Conferences

GlobeNewswire 11/8/2016 Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations

GlobeNewswire 11/7/2016 MorphoSys AG Reports Results for the First Nine Months of 2016

GlobeNewswire 11/3/2016 MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...

GlobeNewswire 11/2/2016 MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...

GlobeNewswire 10/28/2016 MorphoSys to Host Q3 2016 Conference Call on November 7, 2016

GlobeNewswire 10/20/2016 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody

GlobeNewswire 10/17/2016 MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference

GlobeNewswire 10/1/2016 MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...

GlobeNewswire 10/1/2016 Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...

GlobeNewswire 9/29/2016 MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis

Soc. Generale Index/Partizip. Zer.../ DE000SQ79WT1 /

If you wish to receive reply to your feedback, please provide your email address.